InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company's novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332.
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
InnoCare Appoints Xin Fu as Chief Financial Officer
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332
Data of InnoCare’s Oncology Pipelines Presented at the 65th Meeting of ASH